Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.20 USD

51.20
2,122,230

+0.77 (1.53%)

Updated Jul 24, 2024 04:00 PM ET

After-Market: $51.22 +0.02 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (186 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Shire Files Marketing Application for Lifitegrast in Europe

by Zacks Equity Research

Shire plc (SHPG) submitted a Marketing Authorization Application (MAA) for lifitegrast for the treatment of dry eye disease in Europe.

    Are Amgen's New Drugs Doing Well Enough to Drive Sales?

    by Zacks Equity Research

    Higher volumes of Amgen, Inc.'s (AMGN) new products may not be enough to offset the lost sales due to the decline in mature brands.

      Pacira Pharmaceuticals Focuses on Exparel's Label Expansion

      by Zacks Equity Research

      Pacira Pharmaceuticals, Inc. (PCRX) is making efforts to expand its flagship product, Exparel, which was launched in 2012.

        Novo Nordisk (NVO) Beats on Q2 Earnings, Revenues Miss

        by Zacks Equity Research

        Novo Nordisk A/S (NVO) beat earnings estimates but missed revenue estimates in Q2. Robust performance for Victoza and Tresiba will drive growth.

          Arpita Dutt headshot

          Forget Teva (TEVA), Buy These 4 Drug Stocks Instead

          by Arpita Dutt

          With generic drugmakers like Teva (TEVA) under pressure, here is a look at four drug stocks that look well-positioned.

            Alnylam (ALNY) Q2 Loss Narrower than Expected, Sales Miss

            by Zacks Equity Research

            Alnylam's (ALNY) second-quarter results were mixed with the company reporting a narrower-than-expected loss but sales missed estimates.

              Intrexon (XON) Q2 Loss Narrower than Expected, Revenues Miss

              by Zacks Equity Research

              Intrexon Corporation (XON) incurred narrower than expected loss and missed revenue estimates in Q2.

                Catalyst (CPRX) Posts Narrower than Expected Loss in Q2

                by Zacks Equity Research

                Catalyst Pharmaceuticals, Inc. (CPRX) reported narrower than expected loss in Q2 and is focused on the development of its pipeline candidate Firdapse.

                  Arpita Dutt headshot

                  Forget Bayer, Buy These 3 Drug Stocks Instead

                  by Arpita Dutt

                  With Bayer (BAYRY) reporting mixed results in the second quarter and lowering its outlook, here is a look at 3 drug stocks which look well positioned.

                    VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y

                    by Zacks Equity Research

                    VIVUS reported dismal second-quarter results wherein its loss widened from the year-ago period on lower sales.

                      Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Rise Y/Y

                      by Zacks Equity Research

                      Emergent's (EBS) earnings and revenues miss estimates in Q2. However, revenue increased year-over-year due to product sales and increase in contract manufacturing revenues.

                        AMAG Pharma (AMAG) Incurs Narrower-than-Expected Loss in Q2

                        by Zacks Equity Research

                        AMAG Pharmaceuticals, Inc. (AMAG) posted narrower-than-expected loss and slightly beat revenue estimates in Q2.

                          Regeneron (REGN) Beats on Q2 Earnings & Sales, Raises View

                          by Zacks Equity Research

                          Regeneron Pharmaceuticals, Inc. (REGN) reported strong second-quarter results wherein both earnings and sales beat expectations on the back of Eylea sales.

                            Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q2

                            by Zacks Equity Research

                            Immune Design (IMDZ) incurred narrower-than-expected loss in Q2. Revenues missed expectations.

                              BioMarin (BMRN) Q2 Loss Narrows, Sales Surpass Estimates

                              by Zacks Equity Research

                              BioMarin Pharmaceutical Inc. (BMRN) reported a narrower-than-expected loss in Q2 and also beat estimates for sales. The biotech also raised its previously issued full year sales outlook.

                                ImmunoGen (IMGN) Q2 Loss Narrows, Sales & Cash Outlook Up

                                by Zacks Equity Research

                                ImmunoGen's (IMGN) Q2 results report a narrower-than-expected loss with revenue beating the estimates. The company also significantly raises the cash and revenue guidance this quarter.

                                  Dr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise

                                  by Zacks Equity Research

                                  Dr. Reddy's Laboratories Ltd.'s (RDY) first-quarter fiscal 2018 earnings per American Depositary Share (ADS) declined year over year while sales increased from the year ago quarter.

                                    Sanofi (SNY) Q2 Earnings In Line, Sales Lag,'17 View Raised

                                    by Zacks Equity Research

                                    Sanofi (SNY) Q2 results were mixed as it reported in-line earnings and slightly missed sales expectations. However, the company raised its 2017 earnings guidance.

                                      AbbVie (ABBV) Tops Q2 Earnings & Revenues, Outlook Intact

                                      by Zacks Equity Research

                                      AbbVie's (ABBV) Q2 earnings surpass estimates with revenues also marginally beating the same. Sales of its lead marketed drug, Humira, rise year over year.

                                        Keryx (KERX) Posts Wider than Expected Loss in Q2, Sales Beat

                                        by Zacks Equity Research

                                        Keryx's (KERX) loss in Q2 was wider than expected but sales beat estimates. The company also raised its 2017 outlook for net U.S. Auryxia product sales.

                                          Alkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat

                                          by Zacks Equity Research

                                          Alkermes plc (ALKS) incurred narrower than expected loss in Q2 but marginally surpassed sales estimates. The company reiterated its 2017 outlook.

                                            Bayer (BAYRY) Q2 Earnings Beat, Sales Miss, Cuts Guidance

                                            by Zacks Equity Research

                                            Bayer AG (BAYRY) topped earnings but missed sales expectations in Q2. The company also lowered its guidance for full-year 2017.

                                              Bristol-Myers (BMY) Beats on Q2 Earnings, Tweaks 2017 View

                                              by Zacks Equity Research

                                              Bristol-Myers (BMY) reports encouraging second-quarter results, beating both earnings and sales estimates.

                                                Alexion (ALXN) Tops Q2 Earnings & Revenues, Ups 2017 View

                                                by Zacks Equity Research

                                                Alexion Pharmaceuticals, Inc. (ALXN) exceeded both earnings and revenue estimates in Q2 and also raised its 2017 guidance.

                                                  Amgen (AMGN) Stock Falls Despite Q2 Earnings & Sales Beat

                                                  by Zacks Equity Research

                                                  Amgen Inc. (AMGN) beat estimates on both earnings & sales in Q2. While Amgen slightly tightened the sales guidance, it raised the earnings outlook backed by its strong performance in the first half.